Madrigal Pharmaceuticals, Inc.
MDGL · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Madrigal Pharmaceuticals, Inc. at a glance
In FY2025, Madrigal Pharmaceuticals, Inc. reported revenue of USD 958,403 thousands, EBITDA of USD -298,591 thousands, EBITDA margin of -31.2%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 180,133 | 958,403 | |||
| EBITDA | -496,779 | -298,591 | |||
| EBITDA margin | -275.8% | -31.2% | |||
| Free cash flow | -457,034 | -190,020 |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas